TASIMELTEON clinical trials

OPEN-LABEL SAFETY STUDY OF A 1-YEAR 20MG DOSE REGIMEN OF TASIMELTEON FOR THE TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER (N24HSWD) IN BLIND INDIVIDUALS WITH NO LIGHT PERCEPTION

This study is looking at a medicine called tasimelteon (Hetlioz) to see if it's safe for blind people who can't see any light and have a sleep problem called Non-24-Hour Sleep-Wake Disorder. They'll be taking a 20mg dose for one year, and doctors will check for any side effects.